ESTRO 35 2016 _____________________________________________________________________________________________________ recurring tumors (actuarial 5-yr 44% vs 0% p<0.05). Four cases of mandibular osteoradionecrosis were seen (cumulative dose range 106-128 Gy). Fifty-three patients received a cumulative dose of 100 Gy or higher. The actuarial 5-year mandibular necrosis rate in this group was 26%.
Material and Methods: Initially, 198 patients were included in the validation cohort. From July 2012-October 2014 further TSH measurements were collected in 171/198 patients, increasing the median follow-up from 22 to 38 months after RT. The endpoint, HT, was defined as TSH>4.0 mU/l. Data were analyzed using a mixture model taking both thyroid volume (Vthyroid) and dose (Dmean) into account. From the repeated blood samples, latency was estimated and both the latency time function and NTCP models in AUH were compared to OUH. Validation was performed using a calibration plot of binned groups of patients showing the clinically observed outcome in the validation cohort compared with the predicted outcome from the original NTCP model.
Results:
With the additional follow-up, 40 patients (20%) developed HT (19 after one TSH assessment). Dmean and Vthyroid were still significant risk factors for HT, OR= 1.11 (1. 06-1.19 ) and OR = 0.85 (0.74-0.93), respectively. The cumulative events showed that 94% (59-100%) of the events would develop within the first five years after RT in the validation cohort, in line with the original cohort's 97% (85-100%). Mean thyroid volumes were 17.4 (OUH) and 17.3 (AUH) cm3, and tolerance estimates around this level showed TD25 = 38 Gy and 34 Gy, respectively, at 15 cm3 and 48 Gy and 42Gy, respectively, at 20 cm3. The calibration plot ( Fig. 1 ) showed good agreement between the observed incidences of HT in the validation group versus the expected probability of HT from the original model. Thus, the NTCP model has external validity in the cohort with multiple blood tests.
Conclusion:
Increasing thyroid dose and a decreasing thyroid volume were confirmed as significant risk factors for radiation-induced HT, which likely develops within the first five years after RT. The calibration plot shows that the original NTCP model has external validity, supporting that risk estimates from the NTCP model may be used to support clinical treatment planning decisions relating to development of hypothyroidism after RT to the neck area. Purpose or Objective: Head and neck cancer (HNC) is the sixth most common type of cancer in Europe. Its early symptoms are usually non-specific and easy to miss, which in many patients lead to late presentation and diagnosis. Main risk factors of HNC include alcohol consumption and smoking. Both of them are usually present in young people, thus health education in this group is of great importance. The aim of the study was to assess the level of HNC awareness among young population in Poland.
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Material and Methods:
An anonymous online survey about HNC was conducted among 1903 people in the age of 18-35 years, mainly students of high schools and universities. The closed-ended questions concerned HNC risk factors, symptoms and prognosis. Participation in the study was voluntary.
Results: 85% of respondents had heard about HNC. The main source of information was the Internet (57%). Seventy-eight percent of participants associated smoking with HNC development, but alcohol consumption was mentioned by less than a half, and human papillomavirus (HPV) infection by approximately ⅓ of them. The main risk factors mentioned by students of non-medical schools included smoking (66%), stress (33%), and excessive sunbathing (32%). One fourth of the respondents (38% when excluding medical students) were unaware of any HNC early symptoms. The symptoms mentioned most often included chronic hoarseness (55%), lump in the neck (52%), and chronic sore throat (51%). Over ¾ of medical students and half of other respondents were aware that early diagnosis is associated with a great chance ________________________________________________________________________________ of cure. In contrast to that, if they noticed the symptoms in themselves, as much as 5% of medical students and 9% of students of other schools would seek medical advice only when they made everyday functioning impossible.
Conclusion:
The level of HNC cancer knowledge among young population is alarmingly low. A large number of students of non-medical schools and universities are unaware of its risk factors and early symptoms. This group would benefit from increasing the number of educational campaigns, which would lead to earlier presentation, diagnosis and treatment of HNC. Purpose or Objective: The aim of this study was to evaluate the parotid glands toxicity and its relationship with the dose in a cohort of head and neck cancer patients treated with IMRT.
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Material and Methods: 78 patients out of 110 treated in our department between January 2011 and October 2015 were included in the analysis. Criteria to select patients were: at least 6 months follow up, the omo-lateral parotid (OP) close to the high (HR) and / or intermediate (IR) risk CTV. Characteristics of the studied patients population are shown in Table1.The GTV, whenever present, CTV HR (regions at high risk of microscopic disease), CTV IR (regions at intermediate risk) and CTV LR (regions at low risk) were contoured on each slice. The targets were expanded 3 mm to obtain the PTVs. The prescribed dose was 66-70 Gy (2 -2.13 Gy /fr) to PTV HR, 59.4 -66 Gy (1.8 -2 Gy/fr) to PTV IR; 56.1Gy (1.7 Gy/fr) to PTV LR. IMRT with Simultaneous Integrated Boost (SIB) technique was used (41patients were treated with Tomotherapy and 36 with VARIAN 21EX). The OP and the CP were contoured; PTV SV1 OP and SV2 CP were defined as overlapping volumes of PTVs and glands. Priority was given to PTV when OP was partially included. The dose limit (Dmean) was <= 25 Gy to the whole contralateral gland (if not close to GTV N) and < 24 Gy to the volume of CP not included in the PTV (external CP). Salivary gland toxicity was assessed weekly, during RT, and at 3, 6, 9, 12, 18 ,24 months after RT and was graduated using the RTOG toxicity scale.
Results:
The dose delivered to the PTVs was 67.9 Gy (range 66-70) 2.02 Gy/fr (1.9 -2.2) to PTV HR, 62.3 Gy (range 58-66) 1.86 Gy/fr (1.7-2) to PTV IR, 55.9 Gy (range 51-60) 1.68 Gy/fr (1.65-2) to PTV LR. The mean dose was 41.56 Gy (range 17.8 -66.8) to OP and 24.9 Gy (range 4.7-39.7) to CP; the external CP received 21.7 Gy mean dose. 36 (46.1%) patients experienced mouth dryness, thickened saliva and altered taste (31 G1 and 5 G2) during RT. At a median follow up of 24 months (range 6-56.2) 19 cases with xerostomia were recorded, 15 (19%) G1 and 4 (5,1%) G2. No G3 was observed. The symptom was recorded on an average of 8 months (range 6-15) after RT. Only 13/36 patients with acute salivary problems experienced late xerostomia.
Conclusion:
In our experience 25 Gy mean dose to the whole contra-lateral parotid, with <24 Gy mean dose to the external CP, even with sacrifice of the OP, allowed our patients to maintain an adequate salivation. 24% of cases experienced G1 and G2 xerostomia. No G3 toxicity was observed.
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Review of thyroid ablation rates with RAI based on I131 uptake in differentiated thyroid carcinoma M. Keys Results: Of the cases analysed 73% were female and 27% male with a mean age of 44 years. The predominant histological subtype was papillary (73%), followed by follicular (22%). Most had early stage disease; Stage I (65%), Stage II (22%), Stage III (13%), 39 cases were pN0 and 29 had pN1 disease. Regarding surgery performed 39 patients had a complete excision CE, 22 had residual disease and there was no information for 7 cases. Thirty seven (37) cases had microscopically positive margins, 26 were negative and it was unknown in 5. Pre RAI ablation, Post op. RAI (I131) uptake in these patients was an average of 3.6 % in pN1 disease and 5.1% in those with pN0 disease. The max uptake was 28%. The extent of the surgery tended to influence the trend of uptake. There was a trend to a higher mean uptake in those who didn't have a CE with an uptake of 0.1-17%, and mean of 6.3%. Patients that had a CE had an uptake of 0-28%, and mean of 3.9%. In the SLRON there was no standard protocol for RAI dosage at the time the patients were treated The mean and range of doses of RAI administered was looked at based on pre-ablation uptake scans. Group 1 had a preablation uptake of <4% and group 2 >4%. For group 1 the mean dose was 3.9GBq with a range 2.2-7.4GBq, and group 2 had a mean of 3.7GBq with a range of 2.8-7.4GBq. Postablative RAI131 scans showed an average of 0.07% uptake with the majority of patients (33) having <0.1% uptake. At the time of analysis 23 patients remained disease free, 10 had metastases (M1) and 2 had died from metastatic disease.
Conclusion:
In those that received RAI ablation, high ablation rates ≥90% were shown despite variability in post -op. I131 uptake and dose of RAI administered. There didn't appear to be an association between those with recurrent or metastatic disease and their pre-ablation uptake rates, it was more associated with original stage.
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Role of perfusion CT in evaluation of tumour response after radiochemotherapy in H&N cancer P. Ferrazza 
